Pfizer and BioNTech's coronavirus vaccine is 91% effective in preventing symptomatic COVID-19 infections in children between 5 and 11, according to clinical trials. Pfizer released the data in advance of the FDA's own review of the safety and efficacy of the shots. It is expected that the FDA will grant emergency use authorization to child-size doses of Pfizer's shot in the coming weeks, after which they will quickly become widely available for the nation's 28 million children between 5 and 11.
- Some children who received the shot, one-third the size of an adult dose, reported mild side effects.
- Pfizer's trial included 2,268 children, two-thirds of whom were given the vaccine. Kids who received the placebo were about 10 times as likely to get symptomatic COVID-19 as those who received the vaccine.
- There were no reports of severe side effects such as myocarditis or pericarditis, both of which have been reported in young men, albeit rarely.